secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001682852-26-000015
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q4 revenue $678M (-30% YoY); net loss $(826)M; FY2025 net loss $(2.8)B
------------------------------------------------------------------------------

- Q4 2025 revenue $678M (-30% YoY); GAAP net loss $(826)M ($(2.11) EPS).
- Full-year 2025 revenue $1.9B (-40% YoY); net loss $(2.8)B ($(7.26) EPS).
- 2026 guidance: up to 10% revenue growth; R&D ~$3.0B; year-end cash $5.5-6.0B.
- U.S. FDA issued Refusal-to-File for seasonal flu vaccine (mRNA-1010); Moderna requested Type A meeting.
- Norovirus Phase 3 fully enrolled; intismeran autogene Phase 2 bladder cancer fully enrolled; data readouts expected 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/0001682852-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/mrna-20260213.htm
  HTML page:      https://secwatch.observer/filing/0001682852-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer